SCHEMBL6790202

SCHEMBL6790202

O=C1CSC(=S)N1CS(=O)(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 8/20 0.56
GSK3B P49841 8/20 0.56
MEN1 O00255 7/20 0.56
KMT2A Q03164 7/20 0.56
GAA P10253 5/20 0.47
ALDH1A1 P00352 5/20 0.45
RECQL P46063 4/20 0.45
MAPT P10636 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
THRB P10828 2/20 0.45
HTT P42858 2/20 0.45
POLB P06746 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
HSD17B10 Q99714 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALPL P05186 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18444310 0.81 GAA (0.45) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL11023531 0.78 MEN1 (0.60) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL11037601 0.77 MEN1 (0.62) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL367565 0.76
SCHEMBL3062340 0.76 GSK3A (0.62) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL11037647 0.75 GSK3A (0.49) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL11037646 0.75 GSK3A (0.49) GSK3AGSK3BMEN1KMT2AGAA
SCHEMBL23930054 0.72
SCHEMBL6417260 0.72
SCHEMBL7478193 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-10-07 US disclosed
EP-1192144-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 EP disclosed
WO-2000076988-A1 RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197268-A1 Method of imaging amyloid deposits using substituted rhodanine derivatives APP, PSEN1, PSEN2 GSK3A 2953/4885GSK3B 2884/4885MEN1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.